To Assess Pharmacokinetics, Safety and Tolerability of TEV-48125 in Japanese and Caucasian Healthy Subjects After a Single Subcutaneous (SC) Administration of TEV-48125

Inclusion Criteria: * The subject is a man or woman, 18 to 55 years of age, inclusive * The subject has a body mass index (BMI) ranging from 17.5 to 28.0 kg/m2, inclusive * The subjects must be in a good health at screening and check-in Additional inclusion criteria for Japanese subjects: * Subject must be a non-naturalized Japanese citizen and hold a Japanese passport * Subject must have/had 2 Japanese parents and 4 Japanese grandparents who are all non naturalized Japanese citizens * Subject has been living outside of Japan for no more than 10 years Additional inclusion criteria for Caucasian subjects: * The subject has/had 2 Caucasian parents and 4 Caucasian grandparents. Caucasian includes White and Hispanic ethnicities. * Additional criteria apply, please contact the investigator for more information Exclusion Criteria: * The subject is a woman who is pregnant or lactating * The subject is suffering from, or has a clinically significant history of, 1 or more of the following: cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, neurological, immunological, hematologic or psychiatric disorder(s) * The subject has a known allergy or sensitivity to injected proteins, including monoclonal antibodies, or any other component of the formulation. In addition, presence of history of allergies requiring acute or chronic treatment * Precipitation in another clinical study of a new investigational drug within 30 days (90 days for biologics) before dosing * Additional criteria apply, please contact the investigator for more information